Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06704009 · ClinicalTrials.gov registry record · Phase 1
NT-101 Topical Ophthalmic Solution in Patients With Wet AMD
A Phase 1 study of Wet Age-related Macular Degeneration and Wet AMD, sponsored by NexThera Co..
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT06704009 is a Phase 1 study of Wet Age-related Macular Degeneration and Wet AMD that is active but no longer recruiting, run by NexThera Co.. The registered enrollment target is 30 participants, below the 421-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06704009, a Phase 1 study of Wet Age-related Macular Degeneration and Wet AMD, is active but no longer recruiting, sponsored by NexThera Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)
Conditions Studied
Interventions
- DRUG NT-101 Low Dose
- DRUG NT-101 High Dose
Study Locations (4)
Maryland
- Elman Retina Group - Rosedale
North Carolina
- Duke Eye Center - Durham
Pennsylvania
- Erie Retina Research - Erie
Texas
- Texas Retina Associates - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2026-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06704009
The ClinicalTrials.gov registry entry for NCT06704009 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 421-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target (93% lower). The listed sponsor is NexThera Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Wet Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which NT-101 Low Dose is the first listed.
NCT06704009 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Maryland, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06704009 about?
NCT06704009 is a clinical study titled "NT-101 Topical Ophthalmic Solution in Patients With Wet AMD". Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)
What is the current status of trial NCT06704009?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-03-11. Estimated completion is 2026-03-30.
What conditions does trial NCT06704009 study?
This clinical trial studies the following conditions: Wet Age-related Macular Degeneration, Wet AMD.
What interventions are being tested in trial NCT06704009?
The interventions under investigation include: NT-101 Low Dose (DRUG), NT-101 High Dose (DRUG).
Who is sponsoring clinical trial NCT06704009?
This trial is sponsored by NexThera Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06704009 being conducted?
This trial has 4 study locations across Maryland, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wet Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
RECRUITING · Phase 3
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ACTIVE NOT RECRUITING
-
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
ACTIVE NOT RECRUITING · Phase 3
-
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.